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Abstract
Objective: This study aimed evaluating histologically and histomorphometrically the response of the conjunctive 
tissue face to the implant of chlorhexidine chips in the subcutaneous tissues of rats. Study Design: In this research 
35 male rats Wistar were used to analyze the biocompatibility and the degradation process of chlorhexidine chip. 
In each animal, it was made 2 incisions for subcutaneous implantation of chlorhexidine chip (test group) and a 
polytetrafluorethylene membrane (control group). The morphological changes in subcutaneous implantations were 
assessed after 1, 3, 5, 7, 10, 14, 21 days. The data were submitted to Friedman nonparametric test to analyze the 
comparisons among observation periods and to allow the comparison among groups. Results: Differences were 
found in the analysis of the inflammatory response when comparing the tested materials (p values ≤ 0.05). In test 
group was observed hemorrhage, edema and intense inflammatory infiltrate predominantly neutrophilic around 
material. From 3-day and subsequent periods was verified granulation tissue externally at this infiltrate. From 
10-day on was observed crescent area of degradation of chlorhexidine chip, associated with neutrophilic and mac-
rophagic infiltrate, that maintained until 21-day. In the control group, moderate inflammatory infiltrate was ob-
served initially, predominantly polymorphonuclear, edema and granulation tissue 3-day period. The inflammatory 
infiltrate was gradually replaced for granulation tissue, culminating in a fibrous capsule. Giant multinucleate cells 
situated at contact interface with the coating was examined since 3-day and persisted until 21-day.  Conclusion: 
The chlorhexidine chip induces an intense acute inflammatory response at subcutaneous tissue of rats. Therefore, 
at conditions of this study was not biocompatible.
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Introduction
Periodontal disease represents a variety of clinical man-
ifestations of a heterogeneous group of infectious disor-
ders. Periodontitis is an episodic and segmental inflam-
matory infection and the natural history of the infection 
is highly variable. Some patients remain stable for many 
years, while other patients have a history of sporadic or 
gradually progressing disease (1).
The vast majority of periodontitis cases responded well 
to conventional nonsurgical periodontal therapy, i.e. 
scaling and root planning (SRP), improved oral hygiene 
and supportive recall. However, certain patients, for 
various reasons, do not respond favorably to mechanical 
therapy alone. For these patients, the use of an appropri-
ate adjunctive antimicrobial is often beneficial (2).
Current periodontal therapy strongly emphasizes sup-
pressing or eradicating specific pathogens. However, 
mechanical debridement may fail to remove pathogenic 
organisms because of their location in subepithelial 
gingival tissue, crevicular epithelial cells, collagenous 
substrata, altered cementum and radicular dentinal tu-
buli, subgingival hard deposits, furcations or other ana-
tomic features complicating adequate instrumentation. 
Moreover, pathogens frequently colonize oral mucosa, 
tongue dorsum, tonsils and other buccal domains and 
may translocate from non-periodontal sites to periodon-
tal crevices (3-4).
As an antiseptic, chlorhexidine (CHX) has been used 
effectively for over than 30 years in the treatment of 
gingival inflammation. It shows a broad spectrum of 
topical antimicrobial activity, effectiveness and sub-
stantivity. On the other hand, subgingival irrigation us-
ing CHX was not effective in the treatment of periodon-
titis because of the lack of significant concentrations for 
sufficient lengths of time within the periodontal pocket 
(3).
Local administration, therefore, may be considered an 
alternative to overcome these problems. Improved pa-
tient compliance, drug access to the site of disease, and 
lower total drug dosage are the main benefits of a con-
trolled delivery device (5). 
A degradable, subgingivally placed drug delivery sys-
tem containing 2.5 mg chlorhexidine gluconate‡ was 
developed(6), but experimental and clinical studies 
demonstrated controversial results about the use of 
CHX chip as an adjunct of SRP in the treatment of peri-
odontal disease (3-10). 
A strong anti-inflammatory effect was associated to 
CHX, by reducing the activity of matrix metalloprotei-
nases (MMPs) (7), the basal concentration of leucocytes 
and the levels of the proinflammatory cytokines (11). 
However, it has been related toxicity effects from CHX 
(12-15), even at a very low concentration (16). This drug 
has been demonstrated to induce an inflammatory reac-
tion (14), tissue necrosis (15) and to retard granulation 
tissue formation and wound healing (13). Besides, CHX 
behaved in a cytotoxic manner toward osteoblasts in 
vitro (17).
Based on the exposed, the aim of this experimental 
study was to evaluate histologically and histomorpho-
metrically the response of the conjunctive tissue face 
to the implant of CHX chips in the subcutaneous tis-
sues of rats. The null hypothesis was that there would be 
no difference between the results obtained after CHX 
chips implantation in rats subcutaneous. The alterna-
tive hypothesis was that there would be a statistically 
significant difference.
Materials and Methods
-Microscopic analysis
The biocompatibility of two types of materials was 
evaluated by morphological alterations in subcutane-
ous tissue of 35 male Wistar rats, weighting between 
150 and 200 g. This research was approved by the Com-
mittee of Ethics in Animal Research of São José dos 
Campos School of Dentistry – UNESP, according to the 
criteria of the animal protocol.
The chlorhexidine-gelatin is a bioresorbable chip con-
taining 2.5mg of chlorhexidine in a gelatin matrix. The 
chip is approximately 5 mm height and was developed 
to be placed in an isolated periodontal pocket. In its 
present formulation, the chip resorbs and releases chlo-
rhexidine in the pocket for approximately 7 to 10 days 
following placement. The average CHX concentration 
remain above 150 ppm at least 7 days (18).
Polytetrafluoroethylene (PTFE) nonporous membrane 
(Tecnoflon-Brasflon, Ind. & Com. Plasticos, São Paulo, 
SP), with 0.13 mm thickness, presents characteristics 
and biocompatibility appropriate to be applied as an 
inflammatory reaction standard material of comparison 
with the material tests(19-20).
Preoperatively, the animals were weighed and se-
dated with analgesic-sedative and muscle-relaxing 
(0.1mL/100g) Rompum (2% aqueous solution of 2-(2,6-
xilidine)-5,6-dihydro-4H-1,3 thiazin, Bayer, Brazil) five 
minutes before administration of general anesthesia 
(0.5mL/100g) Dopalen (ketamine hydrochloride, Agri-
brands do Brasil Ltda, Brazil).
After trichotomy and the asepsis of the dorsal region, 
two longitudinal incisions (2 cm extension) at a distance 
of 4 cm were performed in the medium line. The blunt 
dissection in the subcutaneous connective tissue was 
made through laterally with a round-tip scissor to mate-
rial placement. The membrane was cut in disks of 1 cm 
diameter, and later implanted in the subcutaneous tis-
sue. The CHX chip (test group) was inserted on the right 
side and the PTFE (control group) was placed on the left 
side. The surgical wound was closed with 4-0 monony-
lon-interrupted sutures, for a first intention repair.
The animals were euthanized at 1, 3, 5, 7, 10, 14, 21 days 
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with an anesthetic overdose. The samples containing 
the material were immediately fixed in 10% formalin 
solution and routinely processed for histology.  Longi-
tudinal histological sections with 6 μm thickness were 
stained with hematoxylin and eosin for analysis in light 
microscopy. 
-Histomorphometric analysis
The central point of histological section randomiza-
tion and selection for histomorphometric analysis was 
accomplished randomly, eliminating the occurrence of 
sampling bias(20). The chosen tissue area was submit-
ted for examination with serial microscopic sections. 
From these sections, 3 were randomly chosen for his-
tomorphometric analysis. Subsequently, 8 histological 
fields from each section, in the surgical region, were 
analyzed. At this step, a 40X objective (A-Plan, Carl 
Zeiss, Gottingen, Germany) and an ocular 10X (W-PI, 
Carl Zeiss, Gottingen, Germany) of an optical micro-
scope (Axioskop 40, Carl Zeiss, Gottingen, Germany) 
were used.
Histomorphometric analysis was performed to find 
out qualitative parameters of the inflammatory reac-
tion (19). A blind study was conducted to measure the 
tissue outcome in the area using scores, observing the 
presence of neutrophils, lymphocytes, plasmocytes, 
eosinophils, macrophages. Based on these findings, the 
slides were then classified according to the following 
scores: 0 – Absence (when inflammatory cells were ab-
sent or found only within the blood vessels); 1 – Dis-
crete (when inflammatory cells were sparsely present 
or in very small groups); 2 – Moderate (when inflam-
matory cells were densely present or in some groups); 
3 – Intense (when inflammatory cells were found in the 
entire field or were present in a large number, configur-
ing great severity).
After qualitative analysis and attribution of scores to 
the observed events, the slides were scored according to 
inflammation severity. A ranking scale was established, 
which ordered the slides in increasing degree of inflam-
matory reaction, ranging from absent to high reaction. 
The data were submitted to Friedman nonparametric 
test (Bioestat 5.0 for Windows; Belém, Pará, Brazil) to 
analyze the comparisons among observation periods 
and to allow the comparison among groups (5% signifi-
cance). 
Results
Control group: The histological analysis showed a mod-
erated initial inflammatory infiltrate with polymorpho-
nuclear predominance, edema and granulation tissue. 
The inflammatory infiltration was gradually substituted 
by granulation tissue, which then turned into a fibrous 
capsule formation. Some multinucleated giant cells pre-
sented in the contact interface were observed since the 
3-day and persisted until the 21-day (Fig. 1).
Test group: The histological analysis in the 1-day period 
showed hemorrhage, edema and an intense inflammato-
ry infiltrate with predominance of polymorphonuclear 
Fig. 1. Histological images of the PTFE group: a) 1 day: moderate inflammatory 
infiltrate around the material (Hematoxylin and eosin stain – 100x); b) 7 days: granu-
lation tissue and local inflammatory infiltrate (Hematoxylin and eosin stain – 200x); 
c) 10 days: panoramic view of the place previously occupied by the membrane (He-
matoxylin and eosin stain – 25x); d) 21 days: fibrous capsule with some giant cells 
(Hematoxylin and eosin stain – 200x).
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Fig. 2. Histological images of the CHX group: a) 1 day: intense and diffuse inflam-
matory infiltrate, edema and fibrin net around the material (Hematoxylin and eosin 
stain – 100x); b) 3 days: edema and fibrin net around the material. Inflammatory 
infiltrate permeating the muscle fibers (Hematoxylin and eosin stain – 100x); c) 5 
days: intense and difuse inflammatory infiltrate and edema around the material (He-
matoxylin and eosin stain – 200x); d) 7 days: edema and necrotics area close to the 
material (Hematoxylin and eosin stain – 200x).
Fig. 3. Histological images of the CHX group: a) 10 days: panoramic view of the deg-
radation lacuna of CHX chip (Hematoxylin and eosin stain – 25x); b) 10 days: degra-
dation lacunas filled by neutrophils and macrophages (Hematoxylin and eosin stain 
– 400x); c) 14 days: degradation lacunas (Hematoxylin and eosin stain – 100x); d) 21 
days: macrophages and neutrophils in the degradation lacuna. Externally, granula-
tion tissue with mononuclear infiltrated (Hematoxylin and eosin stain – 200x).
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neutrophils adjacent to the material. The 3-day and sub-
sequent periods showed a granulate tissue outside this 
infiltrate. In the 10-day period, degradation of the ma-
terial was detected, mainly characterized by degrada-
tion lacunas filled by neutrophils and macrophages. The 
degradation process increased with time and persisted 
until the 21-day period (Figs. 2, 3).
-Histomorphometric analysis
The mean values and standard deviation of the in-
flammatory reaction histomorphometry of the studied 
groups for the different periods are shown in table 1. 
Differences were found in the analysis of the inflam-
matory response when comparing the tested materials 
(p values were ≤ 0.05). Nevertheless, when testing the 
influence of the time on the degree of inflammation, the 
inflammatory process did not decrease in a longer ex-
perimental interval in the CHX group. In assessing the 
difference between groups, there was a statistically sig-
nificant difference in the evolution of the inflammatory 
reaction (p <0.0001). When analyzing the evolution of 
the inflammatory response over time, there were differ-
ences in the PTFE group, while there was no difference 
over time in CHX group (Table 2).
Discussion
The result of this study indicated that CHX chip be-
haved in a cytotoxic manner toward subcutaneous tis-
sues of rats. A strong reaction was detected, in the his-
tological analysis, characterized by hemorrhage, edema 
and an intense inflammatory infiltrate, predominantly 
neutrophilic, adjacent to the material. In the subsequent 
periods was verified granulation tissue externally at this 
infiltrate and crescent area of degradation of CHX chip, 
associated with neutrophilic and macrophagic cells. 
However, according to some studies (5, 7, 11), CHX can 
modulate an anti-inflammatory response. Houri-Hadd-
ad et al. (11) showed a decrease of the basal concentra-
tion of leucocytes and the levels of the proinflammatory 
cytokines using CHX diluted to 2000 mg/ml in phos-
phate-buffered saline. CHX chip may also reduce the 
level of prostaglandin E2, a proinflammatory agent that 
can induce pathologic tissue alterations, on gingival cre-
vicular fluid (5). By immunofluorometric assay (IFMA) 
(7), it was observed a decrease in the activity of matrix 
metalloproteinases (MMPs), an important collagenases 
in the development of the inflammatory process (21).
An inflammatory reaction induced by CHX has been 
demonstrated (13-14, 16-17, 22). Chang et al. (12) con-
firmed the toxicity of CHX on cultured human peri-
odontal ligament by inhibiting double-stranded nucleic 
acid content, protein synthesis, and mitochondrial ac-
tivity. The present research is in agreement with these 
studies that found an intense acute inflammatory re-
sponse in the test group. Even in a low concentration, 
CHX have serious toxic effects on gingival fibroblasts 
and may affect wound healing (16). In an in vitro study, 
Giannelli et al. (22) suggested that the direct application 
of CHX during regenerative therapy for the treatment 
of periodontal disease could have serious toxic effects 
on gingival fibroblasts, endothelial cells and, specially, 
on alveolar osteoblasts, thus negatively interfering with 
the early healing phase of the oral disease.  CHX may 
induce cell death by apoptosis and necrosis in cultured 
L929 fibroblasts via endoplasmic reticulum stress (13) 
and have some in vitro cytotoxic effect  on osteoblasts 
(17).
Clinical studies evaluating the use of CHX chip in the 
treatment of periodontal disease presents promising re-
sults. A multicenter clinical trial (6) indicated that the 
Sum of ranks Median Average rank Average values Standard deviation 
CHX PTFE CHX PTFE CHX PTFE CHX PTFE CHX PTFE 
1 day 
4,320,00
0
2,315,00
0 30,000 20,000 108,000 57,875 29,750 22,000 0,1581 0,4051
3 days 
4,125,00
0
2,250,00
0 30,000 20,000 103,125 56,250 29,000 21,750 0,3038 0,3848
5 days 
4,120,00
0
2,315,00
0 30,000 20,000 103,000 57,875 29,000 22,000 0,3038 0,4051
7 days 
4,110,00
0
2,245,00
0 30,000 20,000 102,750 56,125 29,000 21,750 0,3038 0,3848
10 days 
4,075,00
0
2,000,00
0 30,000 20,000 101,875 50,000 28,750 20,750 0,3349 0,3499
14 days 
3,940,00
0
1,455,00
0 30,000 20,000 98,500 36,375 28,250 17,750 0,3848 0,5305
21 days 
3,855,00
0 875,000 30,000 10,000 96,375 21,875 28,000 14,000 0,4051 0,4961
Friedman (Fr) 
2,605,48
6
degrees of freedom 13 
(p) < 0.0001 

Table 1. Mean values and standard deviation of the inflammatory reaction histomorphometry of the studied group.
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Comparisons Difference (p) Comparisons Difference (p) 
Rank CHX 1 e CHX 3 19,5 ns Rank CHX 10 e CHX 14 13,5 ns 
Rank CHX 1 e CHX 5 20 ns Rank CHX 10 e CHX 21 22 ns 
Rank CHX 1 e CHX 7 21 ns Rank CHX 10 e PTFE 1 176 < 0.05 
Rank CHX 1 e CHX 10 24,5 ns Rank CHX 10 e PTFE 3 182,5 < 0.05 
Rank CHX 1 e CHX 14 38 ns Rank CHX 10 e PTFE 5 176 < 0.05 
Rank CHX 1 e CHX 21 46,5 ns Rank CHX 10 e PTFE 7 183 < 0.05 
Rank CHX 1 e PTFE 1 200,5 < 0.05 Rank CHX 10 e PTFE 10 207,5 < 0.05 
Rank CHX 1 e PTFE 3 207 < 0.05 Rank CHX 10 e PTFE 14 262 < 0.05 
Rank CHX 1 e PTFE 5 200,5 < 0.05 Rank CHX 10 e PTFE 21 320 < 0.05 
Rank CHX 1 e PTFE 7 207,5 < 0.05 Rank CHX 14 e CHX 21 8,5 ns 
Rank CHX 1 e PTFE 10 232 < 0.05 Rank CHX 14 e PTFE 1 162,5 < 0.05 
Rank CHX 1 e PTFE 14 286,5 < 0.05 Rank CHX 14 e PTFE 3 169 < 0.05 
Rank CHX 1 e PTFE 21 344,5 < 0.05 Rank CHX 14 e PTFE 5 162,5 < 0.05 
Rank CHX 3 e CHX 5 0,5 ns Rank CHX 14 e PTFE 7 169,5 < 0.05 
Rank CHX 3 e CHX 7 1,5 ns Rank CHX 14 e PTFE 10 194 < 0.05 
Rank CHX 3 e CHX 10 5 ns Rank CHX 14 e PTFE 14 248,5 < 0.05 
Rank CHX 3 e CHX 14 18,5 ns Rank CHX 14 e PTFE 21 306,5 < 0.05 
Rank CHX 3 e CHX 21 27 ns Rank CHX 21 e PTFE 1 154 < 0.05 
Rank CHX 3 e PTFE 1 181 < 0.05 Rank CHX 21 e PTFE 3 160,5 < 0.05 
Rank CHX 3 e PTFE 3 187,5 < 0.05 Rank CHX 21 e PTFE 5 154 < 0.05 
Rank CHX 3 e PTFE 5 181 < 0.05 Rank CHX 21 e PTFE 7 161 < 0.05 
Rank CHX 3 e PTFE 7 188 < 0.05 Rank CHX 21 e PTFE 10 185,5 < 0.05 
Rank CHX 3 e PTFE 10 212,5 < 0.05 Rank CHX 21 e PTFE 14 240 < 0.05 
Rank CHX 3 e PTFE 14 267 < 0.05 Rank CHX 21 e PTFE 21 298 < 0.05 
Rank CHX 3 e PTFE 21 325 < 0.05 Rank PTFE 1 e PTFE 3 6,5 ns 
Rank CHX 5 e CHX 7 1 ns Rank PTFE 1 e PTFE 5 0 ns 
Rank CHX 5 e CHX 10 4,5 ns Rank PTFE 1 e PTFE 7 7 ns 
Rank CHX 5 e CHX 14 18 ns Rank PTFE 1 e PTFE 10 31,5 ns 
Rank CHX 5 e CHX 21 26,5 ns Rank PTFE 1 e PTFE 14 86 ns 
Rank CHX 5 e PTFE 1 180,5 < 0.05 Rank PTFE 1 e PTFE 21 144 < 0.05 
Rank CHX 5 e PTFE 3 187 < 0.05 Rank PTFE  3 e PTFE  5 6,5 ns 
Rank CHX 5 e PTFE 5 180,5 < 0.05 Rank PTFE  3 e PTFE  7 0,5 ns 
Rank CHX 5 e PTFE 7 187,5 < 0.05 Rank PTFE  3 e PTFE  10 25 ns 
Rank CHX 5 e PTFE 10 212 < 0.05 Rank PTFE  3 e PTFE  14 79,5 ns 
Rank CHX 5 e PTFE 14 266,5 < 0.05 Rank PTFE  3 e PTFE  21 137,5 < 0.05 
Rank CHX 5 e PTFE 21 324,5 < 0.05 Rank PTFE 5 e PTFE 7 7 ns 
Rank CHX 7 e CHX 10 3,5 ns Rank PTFE 5 e PTFE 10 31,5 ns 
Rank CHX 7 e CHX 14 17 ns Rank PTFE 5 e PTFE 14 86 ns 
Rank CHX 7 e CHX 21 25,5 ns Rank PTFE 5 e PTFE 21 144 < 0.05 
Rank CHX 7 e PTFE 1 179,5 < 0.05 Rank PTFE 7 e PTFE 10 24,5 ns 
Rank CHX 7 e PTFE 3 186 < 0.05 Rank PTFE 7 e PTFE 14 79 ns 
Rank CHX 7 e PTFE 5 179,5 < 0.05 Rank PTFE 7 e PTFE 21 137 < 0.05 
Rank CHX 7 e PTFE 7 186,5 < 0.05 Rank PTFE 10 e PTFE 14 54,5 ns 
Rank CHX 7 e PTFE 10 211 < 0.05 Rank PTFE 10 e PTFE 21 112,5 ns 
Rank CHX 7 e PTFE 14 265,5 < 0.05 Rank PTFE 14 e PTFE 21 58 ns 
Rank CHX 7 e PTFE 21 323,5 < 0.05 

Table 2. Friedman test of the inflammatory reaction histomorphometry of the studied group.
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adjunctive use of CHX chip is a clinically safe and ef-
fective treatment option for long-term management of 
chronic periodontitis. CHX chip, when used as an ad-
junct to SRP, significantly reduces loss of alveolar bone, 
improve the clinical parameters and modify the subgin-
gival flora (3, 5, 18).
Otherwise, Carvalho et al. (8) failed to observe any ad-
junctive effect on subgingival placement of CHX chips 
after SRP. Grisi et al. (9) concluded that CHX chip did 
not provide any clinical and microbiological bene-fit 
beyond that achieved with conventional SRP, after a 
9-month period. CHX chip treatment of adult perio-
dontitis lesions provides little or no additional antimi-
crobial benefits in comparison to thorough SRP alone 
(10). In a review study, Cosny et al. (4) concluded that 
the clinical and microbiological data currently available 
on the CHX chip are limited and conflicting and more 
research are needed to elucidate the additional value of 
the CHX chip when uses as an adjunct to scaling and 
rooting planning. 
CHX chip consists in a degradable matrix of cross-
linked hydrolyzed gelatin (18). According to the present 
study, the CHX chip degradation process persisted un-
til the 21-day period. Comparing to the control group, 
CHX chip presents a strong inflammatory reaction that 
can put in check the biocompatibility of the material. 
The CHX chip could be an important additional item in 
the treatment of periodontal disease that not responds 
well to the traditional treatment. However, unfortu-
nately, with the actually results about the CHX chip, the 
real benefit is not sure, and more studies are needed to 
evaluate the cytotoxic effect of CHX, and the biocom-
patibility of CHX chip.
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